Healthcare -
Biotechnology - NASDAQ - US
$ 0.469
0.428 %
$ 3.26 M
Market Cap
-0.11
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Hepion Pharmaceuticals, Inc.
| Current Assets | 17.5 M |
| Cash & Short-Term Investments | 14.8 M |
| Receivables | 0 |
| Other Current Assets | 2.7 M |
| Non-Current Assets | 607 K |
| Long-Term Investments | 0 |
| PP&E | 242 K |
| Other Non-Current Assets | 364 K |
| Current Liabilities | 5.29 M |
| Accounts Payable | 2.35 M |
| Short-Term Debt | 116 K |
| Other Current Liabilities | 2.83 M |
| Non-Current Liabilities | 5.52 M |
| Long-Term Debt | 93.1 K |
| Other Non-Current Liabilities | 5.43 M |
EFFICIENCY
Earnings Waterfall
Hepion Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 67.1 K |
| Gross Profit | -67.1 K |
| Operating Expenses | 48.4 M |
| Operating Income | -48.4 M |
| Other Expenses | 478 K |
| Net Income | -48.9 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Hepion Pharmaceuticals, Inc.
| Net Income | -48.9 M |
| Depreciation & Amortization | 67.1 K |
| Capital Expenditures | -14.3 K |
| Stock-Based Compensation | 1.34 M |
| Change in Working Capital | 2.97 M |
| Others | 6.74 M |
| Free Cash Flow | -40.9 M |
Wall Street Analysts Price Targets
Hepion Pharmaceuticals, Inc.
HEPA has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
HEPA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Hepion Pharmaceuticals, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Nov 27, 2023
|
Bought
7.62 K USD
|
Wijngaard Peter
Director
|
+ 2500
|
3.05 USD |
|
1 year ago
Nov 24, 2023
|
Bought
7.72 K USD
|
Wijngaard Peter
Director
|
+ 2500
|
3.09 USD |
|
1 year ago
Sep 19, 2023
|
Bought
5.64 K USD
|
Wijngaard Peter
Director
|
+ 1000
|
5.64 USD |
|
1 year ago
Sep 15, 2023
|
Bought
4.62 K USD
|
Wijngaard Peter
Director
|
+ 861
|
5.37 USD |
|
1 year ago
Sep 15, 2023
|
Bought
758 USD
|
Wijngaard Peter
Director
|
+ 139
|
5.45 USD |
|
1 year ago
Sep 15, 2023
|
Bought
5.82 K USD
|
Wijngaard Peter
Director
|
+ 1000
|
5.82 USD |
|
1 year ago
Sep 18, 2023
|
Bought
8.96 K USD
|
Foster Robert T
CEO and Director
|
+ 1600
|
5.6 USD |
|
1 year ago
Sep 15, 2023
|
Bought
8.64 K USD
|
Foster Robert T
CEO,CSO and Director
|
+ 1600
|
5.4 USD |
|
3 years ago
Feb 16, 2021
|
Bought
22 K USD
|
Wijngaard Peter
Director
|
+ 10000
|
2.2 USD |
|
3 years ago
Feb 18, 2021
|
Bought
40 K USD
|
Foster Robert T
CEO and Director
|
+ 20000
|
2 USD |
|
3 years ago
Feb 18, 2021
|
Bought
20 K USD
|
Cavan John T
Chief Financial Officer
|
+ 10000
|
2 USD |
|
4 years ago
Dec 18, 2020
|
Bought
38.2 K USD
|
Wijngaard Peter
Director
|
+ 20000
|
1.91 USD |
|
4 years ago
Dec 08, 2020
|
Bought
39.4 K USD
|
Foster Robert T
CEO and Director
|
+ 25000
|
1.5767 USD |
|
4 years ago
Dec 02, 2020
|
Bought
10.7 K USD
|
BRANCACCIO JOHN P
Director
|
+ 7000
|
1.53 USD |
|
4 years ago
Dec 01, 2020
|
Bought
19.9 K USD
|
JACOB GARY S
Director
|
+ 12000
|
1.66 USD |
|
4 years ago
Nov 25, 2020
|
Bought
7.29 K USD
|
Cavan John T
Chief Financial Officer
|
+ 4500
|
1.62 USD |
|
6 years ago
Jul 03, 2018
|
Bought
13.4 K USD
|
JACOB GARY S
Director
|
+ 8625
|
1.55 USD |
|
6 years ago
Jul 03, 2018
|
Bought
23.2 USD
|
JACOB GARY S
Director
|
+ 15
|
1.55 USD |
|
6 years ago
Jul 03, 2018
|
Bought
13.4 K USD
|
Cavan John T
CFO
|
+ 8625
|
1.55 USD |
|
6 years ago
Jul 03, 2018
|
Bought
23.2 USD
|
Cavan John T
CFO
|
+ 15
|
1.55 USD |
|
6 years ago
Jul 03, 2018
|
Bought
13.4 K USD
|
Lippa Arnold
Director
|
+ 8625
|
1.55 USD |
|
6 years ago
Jul 03, 2018
|
Bought
23.2 USD
|
Lippa Arnold
Director
|
+ 15
|
1.55 USD |
|
6 years ago
Jul 03, 2018
|
Bought
2.67 K USD
|
BRANCACCIO JOHN P
Director
|
+ 1725
|
1.55 USD |
|
6 years ago
Jul 03, 2018
|
Bought
4.65 USD
|
BRANCACCIO JOHN P
Director
|
+ 3
|
1.55 USD |
|
7 years ago
Jun 20, 2017
|
Bought
13 K USD
|
Cavan John T
CFO
|
+ 20000
|
0.65 USD |
|
8 years ago
Feb 18, 2016
|
Bought
10 K USD
|
SAPIRSTEIN JAMES
Chief Executive Officer
|
+ 10000
|
1 USD |
|
9 years ago
Nov 30, 2015
|
Bought
1.08 K USD
|
SAPIRSTEIN JAMES
Chief Executive Officer
|
+ 500
|
2.15 USD |
|
9 years ago
Nov 23, 2015
|
Bought
4.1 K USD
|
SAPIRSTEIN JAMES
Chief Executive Officer
|
+ 2500
|
1.64 USD |
|
10 years ago
Mar 04, 2014
|
Bought
6.55 K USD
|
BRANCACCIO JOHN P
Director
|
+ 4393
|
1.49 USD |
7. News
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
EDISON, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (the “Company” or “Hepion”), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it has entered into a termination agreement with Pharma Two B Ltd. which terminates the merger agreement between the two parties that was previously entered into on July 19, 2024.
globenewswire.com
- 1 month ago
Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group
KIRYAT ONO, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Pharma Two B , a private, late-stage pharmaceutical company developing innovative combination drugs for neurological disorders, today announced a poster presentation of integrated safety and efficacy data on P2B001 from its Phase 2b and Phase 3 studies in early-stage Parkinson's disease (PD) patients. P2B001 is a fixed, low-dose extended-release (ER) combination of pramipexole, 0.6 mg and rasagiline, 0.75 mg. The data are being presented today by Henry Moore, M.D., Associate Professor of Clinical Neurology, University of Miami, Miller School of Medicine, at the Parkinson's Study Group (PSG) 33 rd Annual Meeting in Nashville, TN.
globenewswire.com
- 1 month ago
Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Transaction Creates Opportunity to Share in Potential Upside of Pharma Two B's Late-Clinical Stage Candidate to Treat Parkinson's Disease
globenewswire.com
- 1 month ago
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson's Disease (“PD”) and Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (“Hepion”), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today jointly announced the filing of a registration statement of Pharma Two B on Form F-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the “SEC”).
globenewswire.com
- 4 months ago
Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer
Monday, Hepion Pharmaceuticals Inc (NASDAQ: HEPA) entered into a definitive merger agreement with Pharma Two B Ltd., a late-clinical stage private Israeli company developing P2B001, a combination product candidate in development for Parkinson's Disease.
benzinga.com
- 5 months ago
Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?
Hepion Pharmaceuticals (NASDAQ: HEPA ) stock is diving on Monday after the biopharmaceutical company announced plans to wind down a clinical trial. A press release from the company notes that it is winding down it Phase 2b ASCEND-NASH study.
investorplace.com
- 8 months ago
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH' Trial
EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it has begun wind-down activities in its ASCEND-NASH Trial, while continuing to explore strategic alternatives, as previously announced in December 2023.
globenewswire.com
- 9 months ago
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, and other chronic diseases, today announced the appointment of Michael Purcell to the Company's Board of Directors, effective March 5, 2024.
globenewswire.com
- 10 months ago
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 980,393 shares of Hepion common stock for gross proceeds to the Company of approximately $2.0 million.
globenewswire.com
- 11 months ago
Hepion Pharmaceuticals to Present at NASH-TAG 2024
EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the 2024 NASH-TAG Conference, which is being held January 4-6, 2024, in Park City, Utah.
globenewswire.com
- 1 year ago
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
Restructuring program purpose is to preserve capital and optimize clinical development program Management plans to continue to evaluate its Phase 2b ASCEND-NASH clinical trial taking in account current market environment Cash runway extended into Q2 2025 EDISON, N.J., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that its Board of Directors has approved a strategic restructuring plan with the objective of preserving capital by initially reducing operating costs by approximately 60% going forward.
globenewswire.com
- 1 year ago
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
EDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it will present at the 7th Obesity & NASH Drug Development Summit taking place November 27 – 29, 2023 in Boston.
globenewswire.com
- 1 year ago
8. Profile
Summary
Hepion Pharmaceuticals, Inc. HEPA
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 3.26 M
Dividend Yield
0.00%
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Contact
399 Thornall Street, Edison, NJ, 08837
https://www.hepionpharma.com
IPO
Date
Feb. 10, 2014
Employees
22
Officers
Mr. John Patrick Brancaccio CPA
Interim Chief Executive Officer, Interim Chief Financial Officer & Chairman of the Board
Sharen Pyatetskaya
Director of Investor Relations